Loading…
ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. expanded their global supply agreements for non-carrier-added lutetium-177 (n.c.a. 177Lu) to support POINT's clinical and commercial development. Financial details were not disclosed.